CSL Highlights Gum Disease Vaccine Partnership With Sanofi Pasteur And Acute Heart Disease Compound At R&D Briefing
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Melbourne-based CSL Limited focused on two new products about to enter the clinic during its Dec. 10 R&D briefing, including a new vaccine to treat severe gum disease, which it is co-developing with Sanofi Pasteur